Results 251 to 260 of about 42,523 (291)

Astroglial CB1 Reveal Sex‐Specific Synaptic Effects of Amphetamine

Glia, Volume 73, Issue 8, Page 1673-1691, August 2025.
Main Points Astroglial CB1 mediate long‐term depression in the NAc through purine release. Amphetamine occludes LTD in male mice by inducing the saturation of A1 receptors. Astroglial CB1 mediate behavioral amphetamine effects in males, but not in females.
Yamuna Mariani, Tommaso Dalla‐Tor, Tommaso Garavaldi, Francisca Julio‐Kalajzić, Doriane Gisquet, Paula Gomez‐Sotres, Astrid Cannich, Giuditta Gambino, Filippo Drago, Roman Serrat, Imane Hurel, Francis Chaouloff, Sandrine Pouvreau, Luigi Bellocchio, Giovanni Marsicano, Ana Covelo   +15 more
wiley   +1 more source

Treatment Experience Using a Micro‐Induction Buprenorphine Protocol for Chronic Pain in Pediatric Sickle Cell Disease

Pediatric Blood &Cancer, Volume 72, Issue 8, August 2025.
ABSTRACT Background Patients with sickle cell disease (SCD) experience painful vaso‐occlusive episodes that increase with age; a subset develops chronic pain (CP). CP is usually managed with acute pain management guidelines despite evidence of ineffectiveness.
Ashwin Patel, Grace Kalmus, Carlton Dampier, Ifeyinwa Osunkwo, Tamara New, Beatrice Gee, Elna Saah   +6 more
wiley   +1 more source

Cannabinoids and Adverse Convulsive Effects: A Pharmacovigilance and Addictovigilance Analysis of Cases Reported in France

Fundamental &Clinical Pharmacology, Volume 39, Issue 4, August 2025.
ABSTRACT Background Seizures after the use of cannabinoids are reported, but no precise descriptions of the characteristics of subjects and factors that may trigger seizures are available. Objectives To study the characteristics and circumstances associated with the occurrence of seizures in individuals using cannabinoids for medical or recreational ...
Marie‐Laure Laroche, Marion Labetoulle, Emilie Jouanjus, Edeltraut Kröger, Arsène Zongo   +4 more
wiley   +1 more source

Opioid Therapy in Chronic Pain: Assessment of Clinical Outcomes and Relationships With Endocrine Biomarkers

European Journal of Pain, Volume 29, Issue 6, July 2025.
ABSTRACT Background Long‐term opioid treatment (L‐TOT) may have consequences that are mediated by factors affecting functionality and health‐related quality of life. This study aimed at investigating associations between L‐TOT and clinical outcomes including sustained attention, short‐term and working memory, worst pain intensity, sleep quality, mood ...
Dalia Abou‐Kassem, Pernille Døssing Kwateng Diasso, Per Sjøgren, Katharina Maria Main, Susanne Dam Nielsen, Geana Paula Kurita   +5 more
wiley   +1 more source

Cognitive Function in Patients With Complex Regional Pain Syndrome: No Clear Impairment Found in a Select Patient Sample

European Journal of Pain, Volume 29, Issue 6, July 2025.
ABSTRACT Background Given the impact of chronic pain on cognition, CRPS may affect specific cognitive functions. However, cognitive functioning is rarely assessed in CRPS, and previous studies have examined only limited domains. As a result, it remains unclear which cognitive functions are affected and whether impairments are CRPS‐specific.
Corinne van den Berg, Esther van den Berg, Frank J. P. M. Huygen, Jitske Tiemensma   +3 more
wiley   +1 more source

Responding to reports of nitazene toxicity in Australia

Medical Journal of Australia, Volume 222, Issue 5, Page 216-219, March 2025.
Brendan Clifford, Amy Peacock, Krista J Siefried, John Gobeil, Jennifer L Smith, Nadine Ezard   +5 more
wiley   +1 more source

Addiction to buprenorphine

, 1987
San L, Porta Serra, M.
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Buprenorphine

BMJ Supportive & Palliative Care, 2022
.
Mellar P Davis, Bertrand Behm, Carlos Fernandez   +2 more
openaire   +2 more sources

The effects of buprenorphine in buprenorphine-maintained volunteers

Psychopharmacology, 1997
Buprenorphine is a mu opioid partial agonist currently used as an analgesic, and being developed for the treatment of opioid dependence. The purpose of this study was to determine the abuse liability of parenteral buprenorphine in volunteers maintained on daily sublingual (SL) buprenorphine (8 mg).
Eric C. Strain, Sharon L. Walsh, George E. Bigelow, Ira A. Liebson, Kenzie L. Preston   +4 more
openaire   +3 more sources

The radioimmunoassay of buprenorphine

European Journal of Clinical Pharmacology, 1980
Antisera to buprenorphine were obtained in rabbits immunised with 3-0-carboxymethylbuprenorphine and N-hemisuccinyl-norbuprenorphine conjugated to bovine serum albumin. Using the latter antiserum and tritium labelled buprenorphine a radioimmunoassay have good accuracy and precision was developed for concentrations as low as 50 picograms in 1 ml of ...
M. R. D. Bennett, R A Moore, G. J. Dockray, J. G. Lloyd-Jones, I. R. Flockhart, M. J. Rance, A. J. Bartlett   +6 more
openaire   +3 more sources